SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

NervGen Pharma Corp. (NGEN) News

Follow NervGen Pharma Corp. (NGEN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol NGEN Asset equity Sector Markets 90 days 10 Last 1.83 Updated Nov 12, 2026, 07:44 PM UTC Open live news feed Open NGEN chart & news
L NervGen Shares Rise After Receiving FDA Breakthrough Therapy Designation for NVG-291 to Treat Spinal Cord Injury 02:44 PM EST, 11/12/2026 (MT Newswires) -- NervGen (NGEN) shares rose over 6% on Thursday after it s REGULATION | Nov 12, 2026, 07:44 PM UTC L NervGen doses first participant in Phase 3 RESTORE study The study is evaluating NVG-291 in chronic spinal cord injury. EQUITY | Oct 12, 2026, 11:15 AM UTC L NervGen Pharma: Expects to File Restated Audited Financial Statements for Year Ended Dec. 31, 2025, Including Restated 2024 Comparative Figure and Adjustment to Jan. 1, 2024, Opening Balances >NGEN NervGen Pharma: Expects to File Restated Audited Financial Statements for Year Ended Dec. 31, 2025, Including Restated 2024 Comparative Figure and Adjustment to Jan. 1, 2024, Opening Balances >NGEN NEWS | Sep 25, 2026, 08:35 PM UTC L NervGen Pharma: Restatement Expected to Reduce Previously Reported Accumulated Deficit >NGEN NervGen Pharma: Restatement Expected to Reduce Previously Reported Accumulated Deficit >NGEN NEWS | Sep 25, 2026, 08:34 PM UTC L NervGen Pharma: Restatement Expected to Reduce Previously Reported Warrant Liabilities >NGEN NervGen Pharma: Restatement Expected to Reduce Previously Reported Warrant Liabilities >NGEN NEWS | Sep 25, 2026, 08:34 PM UTC L NervGen Pharma: Restatement Expected to Reduce Previously Reported Stock-Based Compensation Expense >NGEN NervGen Pharma: Restatement Expected to Reduce Previously Reported Stock-Based Compensation Expense >NGEN EQUITY | Sep 25, 2026, 08:34 PM UTC L NervGen Pharma: Adjustments Have No Effect on Cash and Cash Equivalents, Cash Runway, or Business Operations >NGEN NervGen Pharma: Adjustments Have No Effect on Cash and Cash Equivalents, Cash Runway, or Business Operations >NGEN NEWS | Sep 25, 2026, 08:32 PM UTC L NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments NEWS | Sep 25, 2026, 08:31 PM UTC L NervGen to host inaugural R&D Day on Sept. 30, 2026 NervGen (NGEN) announced it will host its inaugural R&D Day on September 30, 2026. EQUITY | Sep 09, 2026, 11:32 AM UTC L NervGen to host inaugural R&D Day on September 30, 2026 NervGen said it will host its inaugural R&D Day on September 30, 2026. EQUITY | Sep 09, 2026, 11:30 AM UTC L NervGen (NGEN) reports Q2 2026 financial results and business updates NervGen (NGEN) reports its second quarter 2026 financial results and provides business updates, according to TradeXchange Newsdesk. EARNINGS | Aug 13, 2026, 11:30 AM UTC